Lucid Diagnostics Inc.
LUCD · NASDAQ
Bulios Fair Price
$1.26
41.2% upside
Current Price
$0.89
According to Bulios Fair Price, LUCD is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Lucid Diagnostics Inc. is a biotechnology company focused on developing diagnostic technologies and tests. The company specializes in diagnostics and disease detection, particularly in the field of gastroenterology. Lucid Diagnostics develops advanced diagnostic tests and devices that enable precise and rapid determination of patients' conditions and identification of potential diseases. The company emphasizes research and development to provide the medical industry with innovative tools and technologies to improve diagnostics and patient care. Lucid Diagnostics aims to contribute to better health outcomes and quality of life for patients through its diagnostic innovations. Lucid Diagnostics Inc. shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on the development of diagnostic technologies with the potential to enhance medical care.
Sector
Healthcare
Industry
Medical - Devices
CEO
Lishan Aklog
Employees
82
Headquarters
New York City
Upcoming events
Earnings
Upcoming earnings report